Rule 45 as a Mandatory Safeguard: Delay in Analyst Report (and Post‑facto Extension) Vitiates Drugs Prosecution; FDA Maharashtra Directed to Build Time‑Bound Digital Monitoring
1) Introduction
The petitioners (directors and the company M/s Oscar Remedies Pvt. Ltd.) sought quashing of the prosecution
in S.C.C. No.637/2023 pending before the Chief Judicial Magistrate, Gadchiroli. The prosecution arose from
sampling of a drug from a retail outlet (M/s City Medical Shop), which was later reported as “not of standard quality.”
Core legal issue: Whether non-compliance with the strict timeline under Rule 45 of the Drugs and Cosmetics Rules, 1945
(Government Analyst to furnish report within 60 days; extension only with reasons) vitiates the prosecution.
Parties: Petitioners (manufacturer/company and its directors) vs. State of Maharashtra (at the instance of Drugs Inspector).
Key dates (as found/treated as undisputed by the Court):
- 12.07.2022: Drugs Inspector visited the shop and drew samples of RTZOL-DSR (Rabeprazole Sodium (EC) + Domperidone (SR) Capsules), Batch No. C-2111250 (Mfg. Nov 2021; Exp. Oct 2023).
- 14.07.2022: Samples sent to the Government Analyst.
- 01.11.2022: Extension sought by Government Analyst (after expiry of 60 days).
- 18.01.2023: Government Analyst (CA) report received stating drug “not of standard quality.”
- 19.04.2023: Notice with CA report served on manufacturer (about four months after receipt of report).
- 23.08.2023: Complaint filed (before expiry of shelf life).
2) Summary of the Judgment
The High Court allowed the writ petition and quashed the prosecution. It held that Rule 45 compliance is essential:
the Analyst’s report must be furnished within 60 days, and if testing within that period is not possible, an extension must be
sought promptly with reasons. In the present case, extension was sought beyond the stipulated 60 days and, in any event,
the record did not show whether the Government granted the extension. These lapses, coupled with administrative inaction
(including lack of reminders and delayed notice to the manufacturer), led the Court to conclude that the prosecution could not continue.
Separately, the Court issued wide administrative directions to the Commissioner, Food and Drugs Administration, Maharashtra, to
ensure time-bound testing, accountability for lapses, capacity augmentation, and creation of a real-time online/web-hosted monitoring system.
3) Analysis
A) Precedents Cited
This decision was the principal authority relied upon by the petitioners and accepted by the Court as directly governing the issue.
The judgment quoted paragraph 14 of Swapnil s/o Liladhar Mane and ors. v. State of Maharashtra, where the Court treated
the 60-day requirement as serving a substantive purpose: preserving the integrity of testing and protecting the accused’s ability to seek rechecking.
The quoted portion underscores three linked ideas that influenced the present ruling:
- Timeliness as a condition for reliable analysis: analysis beyond 60 days was viewed as undermining “standard of quality” assessment accuracy.
- Delay prejudices statutory defence rights: delayed analysis “violates the vital right of the accused to get the sample rechecked.”
- Absence of reasons for delay aggravates the breach: the complaint lacked explanation for delayed analysis, contributing to quashing.
In the present case, the High Court followed the same logic: an Analyst’s report arriving long after receipt of sample,
with extension sought after the 60-day window and without demonstrated governmental grant, was treated as a fatal infirmity.
(ii) “High Court of Karnataka at Bengaluru in Criminal Petition No.8341 of 2018 on 30.08.2024”
This was cited not as a merits precedent on quashing, but as persuasive support for systemic directions to the regulator.
The Bombay High Court noted that Karnataka High Court had already issued directions to the Drugs Controller General (India),
and then issued analogous directions to the Commissioner, FDA Maharashtra, particularly on online/web-hosted tracking of sample testing and reporting.
B) Legal Reasoning
(i) Rule 45 treated as mandatory in effect
The Court emphasized the language and structure of Rule 45:
- Main rule: report “shall” be furnished within 60 days of receipt of sample.
- Proviso: if not possible, the Analyst “shall seek extension” from Government, giving “specific reasons.”
On facts, the Court found two defects:
- Extension sought after the 60-day period (post-facto), defeating the “within 60 days” discipline and the proviso’s purpose of contemporaneous justification.
- No clarity/evidence that Government granted the extension, which meant the delay had no demonstrated legal cover.
(ii) Prejudice to the accused and integrity of prosecution
Although the State argued that the petitioners failed to exercise rights under Section 25(3) and 25(4) of the Drugs and Cosmetic Act, 1940
(re-testing/analysis mechanisms), the Court’s approach prioritised that the State must first comply with the foundational procedural safeguard of Rule 45.
The Court aligned with the rationale in Swapnil s/o Liladhar Mane and ors. v. State of Maharashtra that delayed analysis can impair the accused’s
ability to meaningfully contest the report (including rechecking), thereby undermining the fairness of the prosecution.
(iii) Administrative lethargy treated as legally consequential
The Court noted that:
- The Drugs Inspector did not even send reminders to ensure compliance with Rule 45 timelines.
- After receiving the CA report (18.01.2023), the notice was served on the manufacturer only on 19.04.2023 (about four months later).
Importantly, the Court framed these lapses as doubly harmful: they can allow manufacturers of sub-standard drugs to escape on technicalities,
and they also jeopardize public health by blunting timely enforcement. This reasoning supported both (a) quashing in the individual case due to Rule 45 breach,
and (b) systemic directions to prevent recurrence.
C) Impact
(i) Litigation and prosecution strategy under the Drugs regime
- Heightened scrutiny of Rule 45 timelines: Accused manufacturers/distributors are likely to challenge prosecutions where analyst reports are delayed beyond 60 days without timely, reasoned extension and proof of governmental approval.
- Prosecution must document “extension” compliance: Agencies will need a paper trail showing (a) timely request, (b) reasons, and (c) Government grant—otherwise quashing risk increases.
(ii) Administrative reform through judicial directions
The directions (a)–(g) are operational, measurable, and time-bound (three months for compliance, with reporting and listing for compliance).
If implemented, they can materially change enforcement by:
- creating accountability for officers who miss statutory timelines,
- expanding laboratory capacity if workload causes delay, and
- digitalizing the end-to-end sample tracking/reporting workflow to reduce delay and dispute.
(iii) Public health regulation tension: strict procedure vs. substantive harm
The Court candidly acknowledged the public health stakes—sub-standard drugs must be dealt with sternly—yet held that
procedural safeguards are not dispensable. The judgment thus reinforces a recurring theme in regulatory criminal law:
when the statute prescribes a manner and timeline, the State’s failure can defeat even substantively serious cases.
4) Complex Concepts Simplified
-
Rule 45 (60-day rule): The Government Analyst must test/analyse a drug sample and issue a report within 60 days of receiving it.
If they cannot, they must promptly ask the Government for more time and give written reasons.
-
“Extension” under the proviso: A legally recognized extra period to complete testing—but it is not automatic; it requires reasons and governmental involvement.
Seeking it after the deadline (post-facto) weakens its legitimacy.
-
“Not of standard quality”: A statutory classification indicating the sample does not meet prescribed standards; it can ground prosecution,
but the prosecution must still comply with mandatory procedure.
-
Section 25(3) and 25(4) (re-testing right): Provisions that enable an accused to challenge the Government Analyst’s report by pursuing further testing (typically via the Central Drugs Laboratory).
The Court’s concern is that delayed analysis/reporting can practically impair this right.
-
“Quashing”: The High Court’s power to terminate criminal proceedings where continuing them would be unjust or legally untenable (here, due to Rule 45 non-compliance).
5) Conclusion
This judgment crystallizes a strict operational rule for drugs prosecutions: Rule 45’s 60-day reporting timeline is a substantive procedural safeguard,
and non-compliance—especially where extension is sought after expiry and governmental approval is not shown—can render the prosecution unsustainable.
Beyond case-specific relief, the decision is notable for its governance-oriented directions: it places responsibility on the FDA leadership to enforce timelines,
take strict action for lapses, expand laboratory infrastructure where needed, and implement a real-time online/web-hosted system to monitor sample testing and reporting.
The combined effect is to (i) protect fair trial interests and (ii) push institutional reform so that public health objectives are not defeated by administrative delay.